Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.
Hong SBlood and Marrow Transplant Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.
Brazauskas RCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Hebert KMCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Ganguly SDivision of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
Abdel-Azim HDivision of Hematology, Oncology, and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
LeMaistre CHematology and Bone Marrow Transplant, Sarah Cannon, Nashville, Tennessee.
Aljurf MDSMDepartment of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Olsson RFDepartment of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Bhatt NSFred Hutchinson Cancer Research Center, Seattle, Washington.
Farhadfar NDivision of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.
Yared JABlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.
Yoshimi ADivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, University of Freiburg, Freiburg, Germany.
Seo SDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Gergis UThomas Jefferson University, Philadelphia, Pennsylvania.
English
BACKGROUND The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.
METHODS This study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.
RESULTS The median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.
CONCLUSIONS Patients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.